Table 2.
Clinical and Microbiological Characteristics of HvKP Isolates
| Characteristics | NO.(%) of Isolates | P value | |
|---|---|---|---|
| HvKP (n=68) | Non-HvKP (n=47) | ||
| Demographic characteristics | |||
| Male sex | 43 (63.2) | 35 (74.5) | 0.205 |
| Age (years) (mean ± SD) | 57.01 ± 19.00 | 57.26 ± 16.20 | 0.944 |
| K serotypes | |||
| K1 | 21/68 (30.9) | 2/47 (4.3) | 0.000 |
| K2 | 26/68 (38.2) | 9/47 (19.1) | 0.029 |
| K5 | 12/68 (17.6) | 4/47 (8.5) | 0.164 |
| K20 | 0/68 (0.0) | 2/47 (4.3) | 0.086 |
| K57 | 8/68 (11.8) | 1/47 (2.1) | 0.059 |
| Antimicrobial susceptibility | |||
| Ceftazidime | 13/68 (19.1) | 12/47 (25.5) | 0.093 |
| Ceftriaxone | 14/68 (20.6) | 15/47 (32.0) | 0.028 |
| Cefepime | 13/68 (19.1) | 11/47 (23.4) | 0.030 |
| Cefotaxime | 14/68 (20.6) | 15/47 (32.0) | 0.028 |
| Piperacillin-tazobactam | 12/68 (17.6) | 9/47 (19.1) | 0.273 |
| Cefoperazone-sulbactam | 13/68 (19.1) | 10/47 (21.3) | 0.254 |
| Imipenem | 12/68 (17.6) | 10/47 (21.3) | 0.168 |
| Meropenem | 12/68 (17.6) | 10/47 (21.3) | 0.168 |
| Amikacin | 12/68 (17.6) | 6/47 (12.8) | 0.872 |
| Gentamicin | 13/68 (19.1) | 10/47 (21.3) | 0.254 |
| Ciprofloxacin | 15/68 (22.1) | 14/47 (29.8) | 0.082 |
| Levofloxacin | 14/68 (20.6) | 13/47 (27.7) | 0.088 |
| Aztreonam | 15/68 (22.1) | 14/47 (29.8) | 0.082 |
| Tigecycline | 0/68 (0) | - | - |
| Colistin | 0/68 (0) | - | - |
| Carbapenemase | 12/68 (17.6) | 11/47 (23.4) | 0.448 |
| Diseases | |||
| Cancer | 7 (10.3) | 12 (25.5) | 0.031 |
| Liver abscess | 8 (11.8) | 1 (0.02) | 0.059 |
| Hypertension | 21 (44.7) | 15 (32.0) | 0.907 |
| Diabetes | 18 (26.5) | 8 (17.0) | 0.234 |
| Pulmonary disease | 19 (28.0) | 12 (25.5) | 0.775 |
| Invasive equipment | 33 (48.5) | 21 (44.7) | 0.684 |